Limits...
Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne.

Sadove R - Aesthetic Plast Surg (2008)

Bottom Line: Both patients were extremely pleased with their results at, respectively, 1- and 4-year follow-up evaluations.Patients experienced minimal swelling and redness after injection and no product-related adverse events such as papule and/or nodule formation.The author believes these data suggest that injectable PLLA is a good treatment option for the correction of macular atropic scarring with thin dermis (off-label use), particularly compared with other injectable fillers currently used for this indication that have shorter durations of effect.

View Article: PubMed Central - PubMed

Affiliation: Department of Plastic Surgery, University of Florida College of Medicine, 9227 SW 43rd Lane, Gainesville, FL 32608, USA. rcraigs@bellsouth.net

ABSTRACT
Acne vulgaris affects up to 80% of people 11 to 30 years of age, and scarring can occur for up to 95% of these patients. Scarring may be pitted or hypertrophic in nature, although in most cases it is atrophic. Atrophic acne scarring follows dermal collagen and fat loss after moderate to severe acne infection. Injectable poly-L-acid (PLLA) is a biocompatible, biodegradable, synthetic polymer device that is hypothesized to enhance dermal volume via the endogenous production of fibroblasts and, subsequently, collagen. The gradual improvements in cutaneous volume observed after treatment with injectable PLLA have been noted to last up to 2 years. The case studies presented describe the use of injectable PLLA to correct dermal fat loss in macular atrophic acne scarring of the cheeks. Two female patients underwent three treatment sessions with injectable PLLA over a 12-week period. At each treatment session, the reconstituted product was injected into the deep dermis under the depressed portion of the scar. Both patients were extremely pleased with their results at, respectively, 1- and 4-year follow-up evaluations. Patients experienced minimal swelling and redness after injection and no product-related adverse events such as papule and/or nodule formation. The author believes these data suggest that injectable PLLA is a good treatment option for the correction of macular atropic scarring with thin dermis (off-label use), particularly compared with other injectable fillers currently used for this indication that have shorter durations of effect.

Show MeSH

Related in: MedlinePlus

Case study 1. Photographs before (a) and 1 year after (b) the final treatment of a 21-year-old patient who underwent three injectable poly-l-lactic acid treatment (dermal lipoatrophy) sessions for facial “scarring” caused by chronic acne
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2696608&req=5

Fig1: Case study 1. Photographs before (a) and 1 year after (b) the final treatment of a 21-year-old patient who underwent three injectable poly-l-lactic acid treatment (dermal lipoatrophy) sessions for facial “scarring” caused by chronic acne

Mentions: Injectable PLLA was used to treat two women, ages 21 (Fig. 1) and 45 years (Fig. 2), with dermal fat atrophy caused by chronic and severe facial acne of the cheeks. Both patients, in good health with no comorbid diseases or infections, signed consent forms before treatment.Fig. 1


Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne.

Sadove R - Aesthetic Plast Surg (2008)

Case study 1. Photographs before (a) and 1 year after (b) the final treatment of a 21-year-old patient who underwent three injectable poly-l-lactic acid treatment (dermal lipoatrophy) sessions for facial “scarring” caused by chronic acne
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2696608&req=5

Fig1: Case study 1. Photographs before (a) and 1 year after (b) the final treatment of a 21-year-old patient who underwent three injectable poly-l-lactic acid treatment (dermal lipoatrophy) sessions for facial “scarring” caused by chronic acne
Mentions: Injectable PLLA was used to treat two women, ages 21 (Fig. 1) and 45 years (Fig. 2), with dermal fat atrophy caused by chronic and severe facial acne of the cheeks. Both patients, in good health with no comorbid diseases or infections, signed consent forms before treatment.Fig. 1

Bottom Line: Both patients were extremely pleased with their results at, respectively, 1- and 4-year follow-up evaluations.Patients experienced minimal swelling and redness after injection and no product-related adverse events such as papule and/or nodule formation.The author believes these data suggest that injectable PLLA is a good treatment option for the correction of macular atropic scarring with thin dermis (off-label use), particularly compared with other injectable fillers currently used for this indication that have shorter durations of effect.

View Article: PubMed Central - PubMed

Affiliation: Department of Plastic Surgery, University of Florida College of Medicine, 9227 SW 43rd Lane, Gainesville, FL 32608, USA. rcraigs@bellsouth.net

ABSTRACT
Acne vulgaris affects up to 80% of people 11 to 30 years of age, and scarring can occur for up to 95% of these patients. Scarring may be pitted or hypertrophic in nature, although in most cases it is atrophic. Atrophic acne scarring follows dermal collagen and fat loss after moderate to severe acne infection. Injectable poly-L-acid (PLLA) is a biocompatible, biodegradable, synthetic polymer device that is hypothesized to enhance dermal volume via the endogenous production of fibroblasts and, subsequently, collagen. The gradual improvements in cutaneous volume observed after treatment with injectable PLLA have been noted to last up to 2 years. The case studies presented describe the use of injectable PLLA to correct dermal fat loss in macular atrophic acne scarring of the cheeks. Two female patients underwent three treatment sessions with injectable PLLA over a 12-week period. At each treatment session, the reconstituted product was injected into the deep dermis under the depressed portion of the scar. Both patients were extremely pleased with their results at, respectively, 1- and 4-year follow-up evaluations. Patients experienced minimal swelling and redness after injection and no product-related adverse events such as papule and/or nodule formation. The author believes these data suggest that injectable PLLA is a good treatment option for the correction of macular atropic scarring with thin dermis (off-label use), particularly compared with other injectable fillers currently used for this indication that have shorter durations of effect.

Show MeSH
Related in: MedlinePlus